ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia
Science & Medicine 
Read more
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
Science & Medicine 
Read more
ImCheck Therapeutics Named to French Tech 120 for Sixth Consecutive Year
Leadership & Corporate 
Read more

ESMO 2025

From  Oct 17, 2025  to  Oct 21, 2025 

Read more

SITC 2025

From  Nov 05, 2025  to  Nov 09, 2025 

Read more

ASH 2025

From  Dec 06, 2025  to  Dec 09, 2025 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news